Amedeo Smart

Free Medical Literature Service


 

Amedeo

Breast Cancer

  Free Subscription

Articles published in
Int J Cancer
    November 2017
  1. SCHAIRER C, Pfeiffer RM, Gadalla SM
    Autoimmune diseases and breast cancer risk by tumor hormone-receptor status among elderly women.
    Int J Cancer. 2017 Nov 16. doi: 10.1002/ijc.31148.
    >> Share

  2. BRANDT J, Borgquist S, Almgren P, Forsti A, et al
    Thyroid associated genetic polymorphisms in relation to breast cancer risk in the Malmo Diet and Cancer Study.
    Int J Cancer. 2017 Nov 14. doi: 10.1002/ijc.31156.
    >> Share

  3. BARRDAHL M, Canzian F, Gaudet MM, Gapstur SM, et al
    A comprehensive analysis of polymorphic variants in steroid hormone and IGF-1 metabolism and risk of in situ breast cancer: results from the Breast and Prostate Cancer Cohort (BPC3) Consortium.
    Int J Cancer. 2017 Nov 7. doi: 10.1002/ijc.31145.
    >> Share

    October 2017
  4. SCHMIDT ME, Wiskemann J, Schneeweiss A, Potthoff K, et al
    Determinants of physical, affective, and cognitive fatigue: During breast cancer therapy and 12 months follow-up.
    Int J Cancer. 2017 Oct 30. doi: 10.1002/ijc.31138.
    >> Share

  5. HIRKO KA, Chai B, Spiegelman D, Campos H, et al
    Erythrocyte membrane fatty acids and breast cancer risk: A prospective analysis in the Nurses' Health Study II.
    Int J Cancer. 2017 Oct 26. doi: 10.1002/ijc.31133.
    >> Share

  6. KEINAN-BOKER L, Levine H, Leiba A, Derazne E, et al
    Adolescent obesity and adult male breast cancer in a cohort of 1,382,093 men.
    Int J Cancer. 2017 Oct 21. doi: 10.1002/ijc.31121.
    >> Share

  7. YU J, Wang X, Lu Q, Wang J, et al
    Extracellular 5'-nucleotidase (CD73) promotes human breast cancer cells growth through AKT/GSK-3beta/beta-catenin/cyclinD1 signaling pathway.
    Int J Cancer. 2017 Oct 19. doi: 10.1002/ijc.31112.
    >> Share

  8. SUROWY H, Varga D, Burwinkel B, Marme F, et al
    A low frequency haplotype spanning SLX4/FANCP constitutes a new risk locus for early-onset breast cancer (<60 years) and is associated with reduced DNA repair capacity.
    Int J Cancer. 2017 Oct 16. doi: 10.1002/ijc.31105.
    >> Share

  9. ZHAO B, Zhao H
    Impact of clinicopathological characteristics on the efficacy of neoadjuvant therapy in patients with human epidermal growth factor receptor-2-positive breast cancer.
    Int J Cancer. 2017 Oct 11. doi: 10.1002/ijc.31097.
    >> Share

  10. CONRAD C, Gotte M, Schlomann U, Roessler M, et al
    ADAM8 expression in breast cancer derived metastases: Functional implications on MMP-9 expression and transendothelial migration in breast cancer cells.
    Int J Cancer. 2017 Oct 7. doi: 10.1002/ijc.31090.
    >> Share

  11. NAGAPRASHANTHA LD, Adhikari R, Singhal J, Chikara S, et al
    Translational Opportunities for Broad-Spectrum Natural Phytochemicals and Targeted Agent Combinations in Breast Cancer.
    Int J Cancer. 2017 Oct 4. doi: 10.1002/ijc.31085.
    >> Share

    September 2017
  12. THAPA B, Bahadur Kc R, Uludag H
    Novel Targets for Sensitizing Breast Cancer Cells to TRAIL-Induced Apoptosis with siRNA Delivery.
    Int J Cancer. 2017 Sep 27. doi: 10.1002/ijc.31079.
    >> Share

  13. GUO S, Jing Y, Burcus NI, Lassiter BP, et al
    Nano-Pulse Stimulation Induces Potent Immune Responses, Eradicating Local Breast Cancer while Reducing Distant Metastases.
    Int J Cancer. 2017 Sep 25. doi: 10.1002/ijc.31071.
    >> Share

  14. WILKE CM, Hess J, Klymenko SV, Chumak VV, et al
    Expression of miRNA-26b-5p and its target TRPS1 is associated with radiation exposure in post-Chernobyl breast cancer.
    Int J Cancer. 2017 Sep 25. doi: 10.1002/ijc.31072.
    >> Share

  15. KIMBUNG S, Markholm I, Bjohle J, Lekberg T, et al
    Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: results from the phase 2 PROMIX trial.
    Int J Cancer. 2017 Sep 22. doi: 10.1002/ijc.31070.
    >> Share

  16. KORCH C, Hall EM, Dirks WG, Ewing M, et al
    Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line.
    Int J Cancer. 2017 Sep 22. doi: 10.1002/ijc.31067.
    >> Share

  17. DE GOOIJER MC, Zhang P, Weijer R, Buil LCM, et al
    The impact of P-glycoprotein and Breast Cancer Resistance Protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors.
    Int J Cancer. 2017 Sep 16. doi: 10.1002/ijc.31052.
    >> Share

  18. WANG S, Huo D, Kupfer S, Alleyne D, et al
    Genetic variation in the Vitamin D related pathway and breast cancer risk in women of African ancestry in the Root Consortium.
    Int J Cancer. 2017 Sep 10. doi: 10.1002/ijc.31038.
    >> Share

  19. LAGENDIJK M, van Maaren MC, Saadatmand S, Strobbe LJ, et al
    Breast conserving therapy and mastectomy revisited: Breast cancer-specific survival and the influence of prognostic factors in 129,692 patients.
    Int J Cancer. 2017 Sep 7. doi: 10.1002/ijc.31034.
    >> Share

    August 2017
  20. BERTRAND KA, Gerlovin H, Bethea TN, Palmer JR, et al
    Pubertal growth and adult height in relation to breast cancer risk in African American women.
    Int J Cancer. 2017 Aug 28. doi: 10.1002/ijc.31019.
    >> Share

  21. WU AH, Vigen C, Butler LM, Tseng CC, et al
    Metabolic conditions and breast cancer risk among Los Angeles County Filipina Americans compared with Chinese and Japanese Americans.
    Int J Cancer. 2017 Aug 26. doi: 10.1002/ijc.31018.
    >> Share

  22. CESPEDES FELICIANO EM, Prentice RL, Aragaki AK, Neuhouser ML, et al
    Methodological Considerations for Disentangling a Risk Factor's Influence on Disease Incidence versus Post-Diagnosis Survival: The Example of Obesity and Breast and Colorectal Cancer Mortality in the Women's Health Initiative.
    Int J Cancer. 2017 Aug 18. doi: 10.1002/ijc.30931.
    >> Share

  23. ZHENG G, Yu H, Hemminki A, Forsti A, et al
    Familial associations of female breast cancer with other cancers.
    Int J Cancer. 2017 Aug 12. doi: 10.1002/ijc.30927.
    >> Share

  24. KVALE R, Myklebust TA, Engholm G, Heinavaara S, et al
    Prostate and breast cancer in four Nordic countries: A comparison of incidence and mortality trends across countries and age groups 1975-2013.
    Int J Cancer. 2017 Aug 10. doi: 10.1002/ijc.30924.
    >> Share

  25. WHITE AJ, Weinberg CR, Park YM, D'Aloisio AA, et al
    Sleep characteristics, light at night and breast cancer risk in a prospective cohort.
    Int J Cancer. 2017 Aug 9. doi: 10.1002/ijc.30920.
    >> Share

    July 2017
  26. NILENDU P, Kumar A, Kumar A, Pal JK, et al
    Breast cancer stem cells as last soldiers eluding therapeutic burn: A hard nut to crack.
    Int J Cancer. 2017 Jul 19. doi: 10.1002/ijc.30898.
    >> Share

  27. SANKATSING VDV, van Ravesteyn NT, Heijnsdijk EAM, de Koning HJ, et al
    Reply to Letter to Editor: 'Questionable method for estimating the influence of mammography screening on breast cancer mortality in the Netherlands.'
    Int J Cancer. 2017 Jul 6. doi: 10.1002/ijc.30873.
    >> Share

  28. SANDSVEDEN M, Manjer J
    Selenium and breast cancer risk: A prospective nested case-control study on serum selenium levels, smoking habits and overweight.
    Int J Cancer. 2017 Jul 6. doi: 10.1002/ijc.30875.
    >> Share

  29. AUTIER P, Boniol M
    Questionable method for estimating the influence of mammography screening on breast cancer mortality in the Netherlands.
    Int J Cancer. 2017 Jul 6. doi: 10.1002/ijc.30874.
    >> Share

  30. SCHIROSI L, De Summa S, Tommasi S, Paradiso A, et al
    VEGF and TWIST1 in a 16-biomarker immunoprofile useful for prognosis of breast cancer patients.
    Int J Cancer. 2017 Jul 5. doi: 10.1002/ijc.30868.
    >> Share

  31. BARRDAHL M, Rudolph A, Hopper JL, Southey MC, et al
    Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium.
    Int J Cancer. 2017 Jul 3. doi: 10.1002/ijc.30859.
    >> Share

    June 2017
  32. FELLER A, Schmidlin K, Bordoni A, Bouchardy C, et al
    Socioeconomic and demographic disparities in breast cancer stage at presentation and survival: A Swiss population-based study.
    Int J Cancer. 2017 Jun 28. doi: 10.1002/ijc.30856.
    >> Share

  33. ALMOZYAN S, Colak D, Mansour F, Alaiya A, et al
    PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation.
    Int J Cancer. 2017 Jun 14. doi: 10.1002/ijc.30834.
    >> Share

    May 2017
  34. KNIGHT JA, Fan J, Malone KE, John EM, et al
    Alcohol consumption and cigarette smoking in combination: a predictor of contralateral breast cancer risk in the WECARE Study.
    Int J Cancer. 2017 May 19. doi: 10.1002/ijc.30791.
    >> Share

  35. VAN DEN ENDE C, Oordt-Speets AM, Vroling H, van Agt HME, et al
    Benefits and harms of breast cancer screening with mammography in women aged 40-49 years: A systematic review.
    Int J Cancer. 2017 May 19. doi: 10.1002/ijc.30794.
    >> Share

  36. LOLAS HAMAMEH S, Renbaum P, Kamal L, Dweik D, et al
    Genomic analysis of inherited breast cancer among Palestinian women: Genetic heterogeneity and a founder mutation in TP53.
    Int J Cancer. 2017 May 9. doi: 10.1002/ijc.30771.
    >> Share

  37. BEAU AB, Lynge E, Njor SH, Vejborg I, et al
    Benefit-to-harm ratio of the Danish breast cancer screening programme.
    Int J Cancer. 2017 May 3. doi: 10.1002/ijc.30758.
    >> Share

    April 2017
  38. SANKATSING VDV, van Ravesteyn NT, Heijnsdijk EAM, Looman CWN, et al
    The effect of population-based mammography screening in Dutch municipalities on breast cancer mortality: 20 years of follow-up.
    Int J Cancer. 2017 Apr 29. doi: 10.1002/ijc.30754.
    >> Share

  39. NARKHEDE AA, Shevde LA, Rao SS
    Biomimetic strategies to recapitulate organ specific microenvironments for studying breast cancer metastasis.
    Int J Cancer. 2017 Apr 25. doi: 10.1002/ijc.30748.
    >> Share

    March 2017
  40. MARTINEZ VG, Crown J, Porter RK, O'Driscoll L, et al
    Neuromedin U alters bioenergetics and expands the cancer stem cell phenotype in HER2-positive breast cancer.
    Int J Cancer. 2017 Mar 24. doi: 10.1002/ijc.30705.
    >> Share

  41. BRINTON LA, Awuah B, Clegg-Lamptey JN, Wiafe-Addai B, et al
    Design considerations for identifying breast cancer risk factors in a population-based study in Africa.
    Int J Cancer. 2017 Mar 13. doi: 10.1002/ijc.30688.
    >> Share

  42. PARK YM, White AJ, Nichols HB, O'Brien KM, et al
    The association between metabolic health, obesity phenotype and the risk of breast cancer.
    Int J Cancer. 2017 Mar 7. doi: 10.1002/ijc.30684.
    >> Share

  43. GADEYNE S, Menvielle G, Kulhanova I, Bopp M, et al
    The turn of the gradient? Educational differences in breast cancer mortality in 18 European populations during the 2000s.
    Int J Cancer. 2017 Mar 7. doi: 10.1002/ijc.30685.
    >> Share

  44. WANG J, Shidfar A, Ivancic D, Ranjan M, et al
    Overexpression of lipid metabolism genes and PBX1 in the contralateral breasts of women with estrogen receptor-negative breast cancer.
    Int J Cancer. 2017 Mar 6. doi: 10.1002/ijc.30680.
    >> Share

  45. VAN DEN BRANDT PA, Schulpen M
    Mediterranean diet adherence and risk of postmenopausal breast cancer: results of a cohort study and meta-analysis.
    Int J Cancer. 2017 Mar 5. doi: 10.1002/ijc.30654.
    >> Share

    February 2017
  46. STROTBEK M, Schmid S, Sanchez-Gonzalez I, Boerries M, et al
    miR-181 elevates Akt signaling by co-targeting PHLPP2 and INPP4B phosphatases in luminal breast cancer.
    Int J Cancer. 2017 Feb 22. doi: 10.1002/ijc.30661.
    >> Share

  47. LIN X, Chen W, Wei F, Zhou BP, et al
    POMC maintains tumor-initiating properties of tumor tissue-derived long-term-cultured breast cancer stem cells.
    Int J Cancer. 2017 Feb 18. doi: 10.1002/ijc.30658.
    >> Share

    January 2017
  48. ROSNER B, Eliassen AH, Toriola AT, Chen WY, et al
    Weight and weight changes in early adulthood and later breast cancer risk.
    Int J Cancer. 2017 Jan 30. doi: 10.1002/ijc.30627.
    >> Share

  49. HALPERN N, Sonnenblick A, Uziely B, Divinsky L, et al
    Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer.
    Int J Cancer. 2017 Jan 24. doi: 10.1002/ijc.30616.
    >> Share

    December 2016
  50. BENNETT L, Quinn J, McCall P, Mallon EA, et al
    High IKKalpha expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)-positive breast cancer.
    Int J Cancer. 2016 Dec 22. doi: 10.1002/ijc.30578.
    >> Share

  51. XU W, Jia G, Cai N, Huang S, et al
    A 16 Yin Yang Gene Expression Ratio Signature for ER+/Node- Breast Cancer.
    Int J Cancer. 2016 Dec 7. doi: 10.1002/ijc.30556.
    >> Share

  52. CHEN S, Wang RX, Liu Y, Yang WT, et al
    PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
    Int J Cancer. 2016 Dec 7. doi: 10.1002/ijc.30552.
    >> Share

  53. MATEJCIC M, de Batlle J, Ricci C, Biessy C, et al
    Biomarkers of folate and vitamin B12 and breast cancer risk: Report from the EPIC cohort.
    Int J Cancer. 2016 Dec 1. doi: 10.1002/ijc.30536.
    >> Share

    November 2016
  54. KARASNEH RA, Murray LJ, Cardwell CR
    Cardiac glycosides and breast cancer risk: A systematic review and meta-analysis of observational studies.
    Int J Cancer. 2016 Nov 15. doi: 10.1002/ijc.30520.
    >> Share

  55. VAN LUIJT PA, Heijnsdijk EA, de Koning HJ
    Cost-effectiveness of the Norwegian breast cancer screening program.
    Int J Cancer. 2016 Nov 11. doi: 10.1002/ijc.30513.
    >> Share

  56. YANG H, Brand JS, Fang F, Chiesa F, et al
    Time-dependent risk of depression, anxiety and stress-related disorders in patients with invasive and in-situ breast cancer.
    Int J Cancer. 2016 Nov 11. doi: 10.1002/ijc.30514.
    >> Share

  57. BODELON C, Oh H, Chatterjee N, Garcia-Closas M, et al
    Association between breast cancer genetic susceptibility variants and terminal duct lobular unit involution of the breast.
    Int J Cancer. 2016 Nov 9. doi: 10.1002/ijc.30512.
    >> Share

  58. BHUSARI P, Vatsa R, Singh G, Parmar M, et al
    Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.
    Int J Cancer. 2016 Nov 3. doi: 10.1002/ijc.30500.
    >> Share

    October 2016
  59. FERRONI P, Santilli F, Cavaliere F, Simeone P, et al
    Oxidant stress as a major determinant of platelet activation in invasive breast cancer.
    Int J Cancer. 2016 Oct 26. doi: 10.1002/ijc.30488.
    >> Share

    September 2016
  60. SIMONSSON M, Bjorner S, Markkula A, Nodin B, et al
    The prognostic impact of COX-2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size.
    Int J Cancer. 2016 Sep 15. doi: 10.1002/ijc.30432.
    >> Share

  61. VAN DER WAAL D, Ripping TM, Verbeek AL, Broeders MJ, et al
    Breast cancer screening effect across breast density strata: A case-control study.
    Int J Cancer. 2016 Sep 15. doi: 10.1002/ijc.30430.
    >> Share

  62. STRAND F, Humphreys K, Eriksson M, Li J, et al
    Longitudinal fluctuation in mammographic percent density differentiates between interval and screen-detected breast cancer.
    Int J Cancer. 2016 Sep 12. doi: 10.1002/ijc.30427.
    >> Share

  63. SYNNOTT NC, Murray A, McGowan PM, Kiely M, et al
    Mutant p53: A Novel Target for the Treatment of Patients with Triple-Negative Breast Cancer?
    Int J Cancer. 2016 Sep 12. doi: 10.1002/ijc.30425.
    >> Share

  64. ROMIEU I, Ferrari P, Chajes V, de Batlle J, et al
    Fiber intake modulates the association of alcohol intake with breast cancer.
    Int J Cancer. 2016 Sep 6. doi: 10.1002/ijc.30415.
    >> Share

  65. HE W, Lindstrom LS, Hall P, Czene K, et al
    Cause-specific mortality in women with breast cancer in situ.
    Int J Cancer. 2016 Sep 4. doi: 10.1002/ijc.30413.
    >> Share

    August 2016
  66. NOMURA SJ, Dash C, Rosenberg L, Yu J, et al
    Adherence to diet, physical activity and body weight recommendations and breast cancer incidence in the Black Women's Health Study.
    Int J Cancer. 2016 Aug 31. doi: 10.1002/ijc.30410.
    >> Share

  67. FRY EA, Taneja P, Inoue K
    Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu.
    Int J Cancer. 2016 Aug 23. doi: 10.1002/ijc.30399.
    >> Share

  68. KIISKI JI, Fagerholm R, Tervasmaki A, Pelttari LM, et al
    FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome.
    Int J Cancer. 2016 Aug 20. doi: 10.1002/ijc.30394.
    >> Share

  69. KIM HJ, Min A, Im SA, Jang H, et al
    Anti-tumor Activity of the ATR Inhibitor AZD6738 in HER2 positive Breast Cancer Cells.
    Int J Cancer. 2016 Aug 8. doi: 10.1002/ijc.30373.
    >> Share

  70. LI J, Humphreys K, Eriksson M, Dar H, et al
    Worse quality of life in young and recently-diagnosed breast cancer survivors compared to female survivors of other cancers: A cross-sectional study.
    Int J Cancer. 2016 Aug 3. doi: 10.1002/ijc.30370.
    >> Share

    July 2016
  71. DARLIX A, Lamy PJ, Lopez-Crapez E, Braccini AL, et al
    Serum NSE, MMP-9 and HER2 extra-cellular domain are associated with brain metastases in metastatic breast cancer patients: Predictive biomarkers for brain metastases?
    Int J Cancer. 2016 Jul 27. doi: 10.1002/ijc.30290.
    >> Share

  72. CADEAU C, Fournier A, Mesrine S, Clavel-Chapelon F, et al
    Postmenopausal breast cancer risk and interactions between body mass index, menopausal hormone therapy use, and vitamin D supplementation: Evidence from the E3N cohort.
    Int J Cancer. 2016 Jul 23. doi: 10.1002/ijc.30282.
    >> Share

  73. KIM SB, Wildiers H, Krop IE, Smitt M, et al
    Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) versus treatment of physician's choice in previously treated HER2-positive advanced breast cancer.
    Int J Cancer. 2016 Jul 18. doi: 10.1002/ijc.30276.
    >> Share

  74. AYRAULT-PIAULT S, Grosclaude P, Daubisse-Marliac L, Pascal J, et al
    Are disparities of waiting times for breast cancer care related to socio-economic factors? A regional population-based study (France).
    Int J Cancer. 2016 Jul 12. doi: 10.1002/ijc.30266.
    >> Share

  75. INOUE K, Fry EA
    Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer.
    Int J Cancer. 2016;139:33-41.
    >> Share

    June 2016
  76. ABREU MH, Abreu PH, Afonso N, Pereira D, et al
    Patterns of recurrence and treatment in male breast cancer: A clue to prognosis?
    Int J Cancer. 2016 Jun 9. doi: 10.1002/ijc.30225.
    >> Share

    May 2016
  77. MANTHRAVADI S, Shrestha A, Madhusudhana S
    Impact of statin use on cancer recurrence and mortality in breast cancer: A systematic review and meta-analysis.
    Int J Cancer. 2016 May 13. doi: 10.1002/ijc.30185.
    >> Share

  78. JOYCE DP, Kerin MJ, Dwyer RM
    Exosome-encapsulated microRNAs as circulating biomarkers for breast cancer.
    Int J Cancer. 2016 May 11. doi: 10.1002/ijc.30179.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016